Manipal Health Enterprises, a prominent healthcare service provider, launched its Initial Public Offering (IPO) today, July 29, 2026. The issue, which aims to raise a substantial Rs 9,275 crore, will remain open for subscription until July 31. Investors can apply for a minimum of 25 equity shares within the price band of Rs 560 to Rs 590 per share.
Issue Details and Company Overview
The IPO comprises a fresh issue of shares worth Rs 8,000 crore and an offer-for-sale (OFS) of 2,16,13,834 shares, amounting to Rs 1,275 crore. Proceeds from the fresh issue are earmarked primarily for debt reduction, acquiring a minority stake in its subsidiary Sahyadri Hospitals, and general corporate purposes.
Incorporated in 2010 and headquartered in Bengaluru, Manipal Health Enterprises operates a vast network of multi-specialty hospitals, clinics, and diagnostic centers across India. As part of the Manipal Group, it offers a comprehensive range of healthcare services, including tertiary and quaternary care, organ transplants, oncology, cardiology, neurology, orthopaedics, and preventive healthcare.
Financial Performance and Pre-IPO Activities
Ahead of its public debut, Manipal Health Enterprises successfully raised Rs 4,160.1 crore from over 130 anchor investors, allocating 7,06,28,768 equity shares at Rs 590 each. Notable anchor investors included ICICI Prudential MF, Kotak MF, Fidelity, Fiam Group Trust, Abu Dhabi Investment Authority, and Nomura India.
For the financial year ending March 31, 2026, the company reported a net profit of Rs 916.52 crore on a revenue of Rs 10,520.52 crore. In the preceding year (FY25), its net profit stood at Rs 1,081.67 crore with a revenue of Rs 8,362.79 crore. The current valuation places the company's market capitalization at over Rs 77,600 crore.
IPO Structure and Grey Market Premium
Manipal Health has reserved shares worth Rs 15 crore for eligible employees, who will receive a discount of Rs 56 per share. The net issue is allocated with 75% for Qualified Institutional Bidders (QIBs), 15% for Non-Institutional Investors (NIIs), and 10% for retail investors. As of the latest reports, the grey market premium (GMP) for Manipal Health shares hovered between Rs 10-12 apiece.
Leading the IPO as book-running lead managers are Kotak Mahindra Capital Company, Axis Capital, Goldman Sachs (India) Securities, Jefferies India, JP Morgan India, UBS Securities India, and DBS Bank. Kfin Technologies Ltd. is serving as the registrar for the issue. Shares are slated to list on both BSE and NSE on Wednesday, August 5.
Brokerage Ratings: A Divided View
Brokerage houses have offered mixed recommendations on the Manipal Health IPO:
- Subscribe for Long-Term: Anand Rathi, ICICIDirect Research, SBI Securities, Master Capital Services, BP Equities, Ventura Securities, AUM Capital, DR Choksey Finserv, and Canara Bank Securities have recommended subscribing for long-term gains. Their positive outlook is largely based on Manipal Health's strong market position, extensive network, robust growth prospects, strategic acquisitions, and planned capacity expansion. Some acknowledge the valuation is full but see scope for appreciation given industry tailwinds.
- Neutral: Arihant Capital Markets and Angel One have assigned a 'Neutral' rating, primarily citing the IPO's aggressive valuation (P/E ratios around 84-85 times FY26 earnings) despite strong fundamentals and market leadership. They suggest waiting for better entry levels.
- Avoid: Swastika Investmart, Kantilal Chhaganlal Securities, and Marwadi Financial Services recommend avoiding the IPO. Their concerns stem from the expensive valuation compared to listed peers (P/E of 85x vs. peers at 65-71x), high dependence on Karnataka for revenue, limited capital for future expansion post debt repayment, and pending legal/tax matters.
Investors are advised to conduct their own due diligence and consult with a financial advisor before making any investment decisions, considering the diverse expert opinions and the company's valuation metrics.